Efficacy of vitamin D in the adjuvant treatment of attention deficit hyperactivity disorder in children

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200055133

Enrollment

Unknown

Registered

2022-01-01

Start date

2022-02-01

Completion date

Unknown

Last updated

2023-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention deficit hyperactivity disorder (ADHD)

Interventions

Therapy group:Oral vitamin D (2000 IU/d)

Control group:Oral placebo

Eligibility

Sex/Gender

All

Age

3 Years to 13 Years

Inclusion criteria

Inclusion criteria: 1. Children diagnosed with ADHD for the first time (diagnosed according to DSM-V criteria); 2. Aged 3-13 years; 3. The concentration of 25(OH)D is between 20ng/ml and 100ng/ml.

Exclusion criteria

Exclusion criteria: 1. History of chronic diseases; 2. Abnormal liver and kidney function; 3. Thyroid and parathyroid diseases; 4. A history of head injury, epilepsy, autism or mental retardation; 5. Iron deficiency anemia; 6. Take vitamin D supplements in the past 2 months; 7. Receive any medical treatment or research not related to ADHD.

Design outcomes

Primary

Measure	Time frame
Conners Parental Scale Score;	—

Secondary

Measure	Time frame
Attention time;Adverse events;	—

Countries

China

Contacts

Public ContactWang Zhiyong

Weifang Maternal and Child Health Hospital (Maternal and Child Health Hospital of Weifang Medical University )

116633009@qq.com+86 13561420160

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026